Compare Enveric Biosciences Inc (ENVB) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nasdaq Inc — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Nasdaq Inc trades at $92.41 (market cap $51.67B). The key difference: Nasdaq Inc is far larger — about 9712.4× Enveric Biosciences Inc's market cap, and Nasdaq Inc pays a 1.23% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NDAQ | |
|---|---|---|
Market Cap | $5.32M | $51.67B |
Sector | Health | Financials |
52-Week High | $17.40 | $100.98 |
52-Week Low | $1.28 | $76.85 |
Enterprise Value | $408.82K | $58.73B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Nasdaq (NDAQ) is trading at $88.01, down 1.35% on the day, with a bullish technical signal supported by moving averages. Fundamentally, the company reported strong revenue growth to $8.26B in 2025 and has consistently beaten earnings estimates, with a robust net income margin of 23.03%. Recent news highlights its core business activity, including new listings and market volume reports.
The outlook is positive, supported by strong analyst consensus and a price target implying ~20% upside. Key opportunities include sustained earnings growth and market leadership, while risks involve execution of strategic investments and sensitivity to capital market activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
